Cardiac, renal, and neurological benefits of preoperative levosimendan administration in patients with right ventricular dysfunction and pulmonary hypertension undergoing cardiac surgery: Evaluation with two biomarkers neutrophil gelatinase-associated lipocalin and neuronal enolase

Therapeutics and Clinical Risk Management

Volumn 12, Issue , 2016, Pages 623-630

  Guerrero Orriach, José Luis ^a   Ariza Villanueva, Daniel ^a   Florez Vela, Ana ^a   Garrido Sánchez, Lourdes ^a,b   Moreno Cortés, María Isabel ^a   Galán Ortega, Manuel ^a   Ramírez Fernández, Alicia ^a   Torres, Juan Alcaide ^a   Fernandez, Concepción Santiago ^a   Arce, Isabel Navarro ^a   Melero Tejedor, José María ^a   Rubio Navarro, Manuel ^a   Cruz Mañas, José ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Acute renal failure; Brain; Kidney; Levosimendan; Preoperative

Indexed keywords

CREATININE; LEVOSIMENDAN; NEURON SPECIFIC ENOLASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ACUTE KIDNEY INJURY SCALE; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE URINE LEVEL; DRUG EFFICACY; ECHOCARDIOGRAPHY; FEMALE; HEART DILATATION; HEART PROTECTION; HEART RIGHT VENTRICLE FAILURE; HEART SURGERY; HEART VALVE SURGERY; HIGH RISK PATIENT; HUMAN; INJURY SCALE; KIDNEY FUNCTION; LUNG ARTERY PRESSURE; MALE; NEUROPROTECTION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREOPERATIVE TREATMENT; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; PULMONARY HYPERTENSION; RENAL PROTECTION;

EID: 84964523021     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S102772     Document Type: Article

References (42)

1. Orriach Guerrero JL, Ramirez Fernandez A, Iglesias P, et al. Preoperative levosimendan. A new way for organoprotection. Curr Pharm Des. 2014;20(34):5476–5483.
2. du Toit EF, Genis A, Opie LH, Pollesello P, Lochner A. A role for the RISK pathway and K(ATP) channels in pre-and post-conditioning induced by levosimendan in the isolated guinea pig heart. Br J Pharmacol. 2008;154(1):41–50.
3. Tritapepe L, De Santis V, Vitale D, et al. Levosimendan pretreatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br J Anaesth. 2009;102(2):198–204.
4. Levin R, Degrange M, Del Mazo C, Tanus E, Porcile R. Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Exp Clin Cardiol. 2012;17(3):125–130.
5. Guerrero-Oriach JL, Navarro-Arce I, Iglesias P, Galán-Ortega M, Rubio-Navarro M, Cruz Mañas J. Preoperative levosimendan for right ventricular dysfunction before heart valve replacement surgery. Rev Esp Cardiol. 2013;66(12):999–1000.
6. Campo A, Mathai SC, Le Pavec J, et al. Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension. Eur Respir J. 2011;38(2):359–367.
7. Sztrymf B, Souza R, Bertoletti L, et al. Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J. 2010;35(6):1286–1293.
8. Ersoy O, Boysan E, Unal EU, et al. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients. Cardiovasc J Afr. 2013;24(7):260–264.
9. Rubio-Regidor M, Pérez-Vela JL, Escribá-Bárcena A, et al. Neurological complications in cardiac surgery post-operative period. Med Intensiva. 2007;31(5):241–250.
10. Karkouti K, Wijeysundera DN, Yau TM, et al. Acute kidney injury after cardiac surgery: focus on modifiable risk factors. Circulation. 2009;119(4):495–502.
11. Haase M, Bellomo R, Devarajan P, et al. Novel biomarkers early predict the severity of acute kidney injury after cardiac surgery in adults. Ann Thorac Surg. 2009;88(1):124–130.
12. Bragadottir G, Redfors B, Ricksten SE. Effects of levosimendan on glomerular filtration rate, renal blood flow, and renal oxygenation after cardiac surgery with cardiopulmonary bypass: a randomized placebo-controlled study. Crit Care Med. 2013;41(10):2328–2335.
13. Varvarousi G, Stefaniotou A, Varvaroussis D, Aroni F, Xanthos T. The role of Levosimendan in cardiopulmonary resuscitation. Eur J Pharmacol. 2014;740:596–602.
14. Kelm RF, Wagenführer J, Bauer H, Schmidtmann I, Engelhard K, Noppens RR. Effects of levosimendan on hemodynamics, local cerebral blood flow, neuronal injury, and neuroinflammation after asphyctic cardiac arrest in rats. Crit Care Med. 2014;42(6):e410–e419.
15. Thakar CV, Arrigain S, Worley S, Yared JP, Paganini EP. A clinical score to predict acute renal failure after cardiac surgery. J Am Soc Nephrol. 2005;16(1):162–168.
16. Roques F, Michel P, Goldstone AR, Nashef SA. The logistic EuroSCORE. Eur Heart J. 2003;24:882–883.
17. Mehta RL, Kellum JA, Shah SV. Acute kidney injury net-work (AKIN): report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31.
18. Parissis JT, Adamopoulos S, Antoniades C, et al. Effects of levosimendan on circulating pro-inflammatory cytokynes and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol. 2004;93(10):1309–1312.
19. Papp Z, Édes I, Fruhwald S, et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2012;159(2):82–87.
20. Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest. 2006;129(5):1313–1321.
21. Thakar CV, Worley S, Arrigain S, Yared JP, Paganini EP. Influence of renal dysfunction on mortality after cardiac surgery: modifying effect of preoperative renal function. Kidney Int. 2005;67(3):1112–1119.
22. Sear JW. Kidney dysfunction in the postoperative period. Br J Anaesth. 2005;95(1):20–32.
23. Tuladhar SM, Püntmann VO, Soni M, Punjabi PP, Bogle RG. Rapid detection of acute kidney injury by plasma and urinary neutrophil gelatinase-associated lipocalin after cardiopulmonary bypass. J Cardiovasc Pharmacol. 2009;53(3):261–266.
24. Prabhu A, Sujatha DI, Ninan B, Vijayalakshmi MA. Neutrophil gelatinase associated lipocalin as a biomarker for acute kidney injury in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. Ann Vasc Surg. 2010;24(4):525–531.
25. Cardoso JS, Ferreira J, de Sá EP, et al. Levosimendan in daily intensive care practice–the experience of 15 centers. The PORTLAND study. J Cardiac Fail. 2004;10:131.
26. Levin RL, Degrange MA, Porcile R, et al. [The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome]. Rev Esp Cardiol. 2008;61(5):471–479.
27. McCully D, Levitsky S. Mitochondrial ATP-sensitive potassium channels in surgical cardioprotection. Arch Biochem Biophys. 2003;420:237–245.
28. Papp JG, Pollesello P, Varró AF, Végh AS. Effect of levosimendan andmilrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs. J Cardiovasc Pharmacol Ther. 2006;11(2):129–135.
29. Metzsch C, Liao Q, Steen S, Algotsson L. Levosimendan cardioprotection reduces the metabolic response during temporary regional coronary occlusion in an open chest pig model. Acta Anaesthesiol Scand. 2007;51(1):86–93.
30. Parissis JT, Paraskevaidis I, Bistola V, et al. Effects of levosimendan on right ventricular function in patients with advanced heart failure. Am J Cardiol. 2006;98(11):1489–1492.
31. Poelzl G, Zwick RH, Grander W, et al. Safety and effectiveness of levosimendan in patients with predominant right heart failure. Herz. 2008;33(5):368–373.
32. Russ MA, Prondzinsky R, Carter JM, et al. Right ventricular function in myocardial infarction complicated by cardiogenic shock: improvement with levosimendan. Crit Care Med. 2009;37(12):3017–3023.
33. Herrmann M, Ebert AD, Galazky I, Wunderlich MT, Kunz WS, Huth C. Neurobehavioral outcome prediction after cardiac surgery: role of neurobiochemical markers of damage to neuronal and glial brain tissue. Stroke. 2000;31(3):645–650.
34. Gao F, Harris DN, Sapsed-Byrne S. Time course of neuronespecific enolase and S-100 protein release during and after coronary artery bypass grafting. Br J Anaesth. 1999;82(2):266–267.
35. Katircioglu SF, Seren M, Parlar AI, et al. Levosimendan effect on spinal cord ischemia-reperfusion injury following aortic clamping. J Card Surg. 2008;23(1):44–48.
36. Lafci B, Yasa H, Ilhan G, al. Protection of the spinal cord from ischemia: comparative effects of levosimendan and iloprost. Eur Surg Res. 2008;41(1):1–7.
37. Roehl AB, Hein M, Loetscher PD, et al. Neuroprotective properties of levosimendan in an in vitro model of traumatic brain injury. BMC Neurol. 2010;10:97.
38. Mayanagi K, Gáspár T, Katakam PV, Busija DW. Systemic administration of diazoxide induces delayed preconditioning against transient focal cerebral ischemia in rats. Brain Res. 2007;1168:106–111.
39. Bantel C, Maze M, Trapp S. Neuronal preconditioning by inhalational anesthetics: evidence for the role of plasmalemmal adenosine triphosphate-sensitive potassium channels. Anesthesiology. 2009;110 (95):986–995.
40. Sponga S, Ivanitskaia E, Potapov E, Krabatsch T, Hetzer R, Lehmkuhl H. Preoperative treatment with levosimendan in candidates for mechanical circulatory support. ASAIO J. 2012;58(1):6–11.
41. Guerrero Orriach JL, Galán Ortega M, Ramírez Fernandez A, et al. Assessing the effect of preoperative levosimendan on renal function in patients with right ventricular dysfunction. J Clin Monit Comput. Epub January 13, 2016.
42. Yilmaz MB, Grossini E, Silva Cardoso JC, et al. Renal effects of levosimendan: a consensus report. Cardiovasc Drugs Ther. 2013;27(6):581–590.